Michael Minogue - ABIOMED Chairman
Chairman
Mr. Michael R. Minogue is the Chairman of the Board, President, Chief Executive Officer of Abiomed, Inc. He has served as our Chief Executive Officer, President and a director since April 2004. In June 2005, he was appointed Chairman of our Board of Directors. Prior to joining us, Mr. Minogue had a twelveyear career at General Electric, or GE. Most recently, Mr. Minogue was Vice President and General Manager of Americas Sales and Marketing for GE Medical Systems Information Technology. From 1997 to 2004, Mr. Minogue held various positions at GE, including General Manager for the Global Positron Emission Technology Business, General Manager, Americas Cardiology IT Sales and General Manager, Global Installed Base. Prior to joining GE, Mr. Minogue served on active duty for four years as an infantry officer in the U.S. Army and received multiple awards. Mr. Minogue received his BS in Engineering Management from the United States Military Academy at West Point and his MBA from the University of Chicago. Mr. Minogue currently serves on the Board of Directors of the Advanced Medical Technology Association and also serves as a Manager on the Board of Managers of Bioventus LLC, a strategic partnership between EW Healthcare Partners and Smith Nephew plc, a global medical technology business based in the United Kingdom. Mr. Minogue is also the Chair of the Board of Directors of the Medical Device Innovation Consortium, a publicprivate partnership created with the objective of advancing medical device regulatory science, and a member of the Board of Directors of Insulet Corporationrationration, a medical device company focused on advancing the treatment of diabetes and other conditions through the use of a proprietary insulin pump. He was formerly on the Board of Directors of LifeCell Corporationrationration, which was acquired by Kinetic Concepts, Inc. in May 2008. since 2005.
| Age | 56 |
| Tenure | 19 years |
| Phone | 978 777-8411 |
| Web | www.abiomed.com |
ABIOMED Management Efficiency
The company has return on total asset (ROA) of 0.0955 % which means that it generated a profit of $0.0955 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1824 %, meaning that it created $0.1824 on every $100 dollars invested by stockholders. ABIOMED's management efficiency ratios could be used to measure how well ABIOMED manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 10 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. ABIOMED has a current ratio of 7.38, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist ABIOMED until it has trouble settling it off, either with new capital or with free cash flow. So, ABIOMED's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like ABIOMED sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for ABIOMED to invest in growth at high rates of return. When we think about ABIOMED's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 8 records | CHAIRMAN Age | ||
| Hon JD | Uranium Energy Corp | 62 | |
| Youpan Liang | Yuexiu Transport Infrastructure | 58 | |
| Paul Barber | ServiceNow | 53 | |
| Spencer Abraham | Uranium Energy Corp | 66 | |
| Michael Long | Arrow Electronics | 65 | |
| Yongjie Liu | Yuexiu Transport Infrastructure | 57 | |
| Douglas DeBruin | Evertz Technologies Limited | N/A | |
| Chunxiu Zhu | Yuexiu Transport Infrastructure | 52 | |
Management Performance
| Return On Equity | 0.18 | |||
| Return On Asset | 0.0955 |
ABIOMED Leadership Team
Elected by the shareholders, the ABIOMED's board of directors comprises two types of representatives: ABIOMED inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ABIOMED. The board's role is to monitor ABIOMED's management team and ensure that shareholders' interests are well served. ABIOMED's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ABIOMED's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Minogue, Chairman, CEO and President Member of Special Stock Option Committee and Member of Executive Committee | ||
| Paul Thomas, Independent Director | ||
| Andrew Greenfield, Vice President - Healthcare Solutions | ||
| Jeannine Rivet, Director | ||
| Ingrid Ward, Director Relations | ||
| Todd Trapp, CFO, Vice President | ||
| Christopher Gorder, Director | ||
| David Weber, Scientific Advisor | ||
| Ian McLeod, Principal Financial Officer, Principal Accounting Officer, Vice President Controller | ||
| Martin Sutter, Independent Director | ||
| Michael Howley, VP and General Manager of Global Sales | ||
| Henri Termeer, Independent Director | ||
| Thorsten Siess, Ex Officer | ||
| William Bolt, Sr. VP of Global Product Operations | ||
| Ingrid Goldberg, Director - Investor Relations | ||
| Matthew Plano, Ex Integration | ||
| Dorothy Puhy, Lead Independent Director | ||
| Michael Tomsicek, CFO, Vice President Treasurer | ||
| Sarah Karr, Communications Mang | ||
| Marc Began, Gen VP | ||
| Eric Rose, Director | ||
| Gerald Austen, Independent Director |
ABIOMED Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ABIOMED a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.18 | |||
| Return On Asset | 0.0955 | |||
| Profit Margin | 0.25 % | |||
| Operating Margin | 0.23 % | |||
| Current Valuation | 16.32 B | |||
| Shares Outstanding | 45.09 M | |||
| Shares Owned By Insiders | 2.02 % | |||
| Shares Owned By Institutions | 97.00 % | |||
| Number Of Shares Shorted | 753.62 K | |||
| Price To Earning | 76.38 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards ABIOMED in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, ABIOMED's short interest history, or implied volatility extrapolated from ABIOMED options trading.
Pair Trading with ABIOMED
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ABIOMED position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ABIOMED will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to ABIOMED could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ABIOMED when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ABIOMED - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ABIOMED to buy it.
The correlation of ABIOMED is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ABIOMED moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ABIOMED moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ABIOMED can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Other Consideration for investing in ABIOMED Stock
If you are still planning to invest in ABIOMED check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ABIOMED's history and understand the potential risks before investing.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |